Cancer cachexia prevention via physical exercise: Molecular mechanisms

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 2, 2013, Pages 111-124

  Gould, Douglas W ^a   Lahart, Ian ^a   Carmichael, Amtul R ^b   Koutedakis, Yiannis ^a,c   Metsios, George S ^a,b,c  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c Centre for Research and Technology   (Greece)

Author keywords

Aerobic training; Cachexia; Cancer; Exercise; Inflammation; Muscle wasting; Physical activity; Resistance training

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FATTY ACID; GAMMA INTERFERON; GLUCOSE TRANSPORTER 4; GLYCEROL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; S6 KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CACHEXIA; CATABOLISM; CELL DAMAGE; CELL SIZE; ENERGY EXPENDITURE; EXERCISE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID COMPOSITION; LIPOLYSIS; MOLECULAR BIOLOGY; MUSCLE ATROPHY; MUSCLE METABOLISM; MUSCLE STRENGTH; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; QUALITY OF LIFE; RESISTANCE TRAINING; REVIEW; RHEUMATOID ARTHRITIS; WEIGHT REDUCTION;

EID: 84879228968     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-012-0096-0     Document Type: Review

References (216)

1. Gordon JN, Green SR, Goggin PM. Cancer cachexia. QJM. 2005;98: 779-88.
2. Tisdale MJ. Mechanisms of Cancer Cachexia. Physiol Rev. 2009;89: 381-410.
3. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res. 2007;13: 1356-61.
4. Tisdale MJ. Cachexia in cancer patients. Nat Rev Genet. 2002;2: 862-71.
5. Monitto CL, Berkowitz D, Lee KM, Pin S, Li D, Breslow M, O'Malley B, Schiller M. Differential gene expression in a murine model of cancer cachexia. American Journal of Physiology - Endocrinology and Metabolism. 2001;281: E289-97.
6. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass Jr HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69: 491-7.
7. Andreyev HJN, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have worse outcomes when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34: 503-9.
8. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer with unresectable pancreatic cancer. Br J Cancer. 1997;75: 106-9.
9. Windsor JA, Hill GL. Risk factors for postoperative pneumonia. The importance of protein depletion. Ann Surg. 1988;208: 209-14.
10. Ryden M, Jocken J, van Harmelen V, Dicker A, Hoffstedt J, Wiren M, Blomqvist L, Mairal A, Langin D, Blaak E, Arner P. Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am J Endocrinol Metab. 2007;292: E1847-55.
11. Russell ST, Hirai K, Tisdale MJ. Role of b3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer. 2001;86: 424-8.
12. Russell ST, Tisdale MJ. Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br J Cancer. 2002;87: 580-4.
13. Klein S, Wolfe RR. Whole body lipolysis & triglyceride fatty acid cycling in cachectic patients with esophageal cancer. J Clin Invest. 1990;86: 1403-8.
14. Hyltander A, Daneryd P, Sandström R, Körner U, Lundholm K. β-Adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer. 2000;36: 330-4.
15. Lira FS, Rosa JC, Zanchi NE, Yamashita AS, Lopes RD, Lopes AC, Batista Jr ML, Seelaender M. Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise. Cell Biochem Funct. 2009;27: 71-5.
16. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative supportive care. J Support Oncol. 2007;5: 157-62.
17. Ardies CM. Exercise, cachexia, and cancer therapy: a molecular rationale. Nutr Cancer. 2002;42: 143-57.
18. Argiles J, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Inc Med Res Rev. 1999;19: 223-48.
19. Balkwill F, Mantovani A. Inflammation & cancer: back to Virchow? THE LANCET. 2001;357: 539-45.
20. Bertevello PS, Seelaender MCL. Heterogeneous response of adipose tissue to cancer cachexia. Brazilian Journal of Medical and Biological Research. 2001;34: 1161-7.
21. Winkler G, Kiss S, Keszthelyi L, Sapi Z, Ory I, Salamon F, Kovacs M, Vargha P, Szekeres O, Speer G, Karadi I, Sikter M, Kaszas E, Dworak O, Gero G, Cseh K. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2003;149: 129-35.
22. Morin CL, Gayles EC, Podolin DA, Wei Y, Xu M, Pagliassotti MJ. Adipose tissue-derived tumor necrosis factor activity correlates with fat cell size but not insulin action in aging rats. Endocrinology. 1998;139: 4998-5005.
23. Llovera M, Garcia-Martinez C, Lopez-Soriano J, Agell N, Lopez-Soriano FJ, Garcia I, Argiles J. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett. 1998;130: 19-27.
24. Llovera M, Garcia-Martinez C, Lopez-Soriano J, Carbo N, Agell N, Lopez-Soriano FJ, Argiles J. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998;98: S0303-72027.
25. Sherry BA, Gelin J, Fong Y, Marano M, Wei H, Cerami A, Lowry SF, Lundholm KG, Moldawer LL. Anticachectin/tumour necrosis factor alpha antibodies attenuate development of cachexia in tumour models. FASEB J. 1989;3: 1956-62.
26. Petersen AM, Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Acute moderate elevation of TNF-α does not affect systemic and skeletal muscle protein turnover in healthy humans. J Clin Endocrinol Metab. 2009;94: 294-9.
27. Ryden M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A, Arner P. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun. 2004;318: 168-75.
28. Price SR, Olivecrona T, Pekala PH. Regulation of lipoprotein lipase synthesis in 3 T3-L1 adipocytes by cachectin. Further proof for identity with tumour necrosis factor. Biochem J. 1986;240: 601-4.
29. Strassman G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992;89: 1681-4.
30. Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, Riccobon A, Derni S, Pallotti G, Amadori D. Serum levels of TNF-a and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer. 1997;5: 130-5.
31. Akedo H, Christensen HN. Nature of insulin action on amino acid uptake by the isolated diaphragm. J Biol Chem. 1962;237: 118-22.
32. Manchester KL, Wool IG. Insulin and incorporation of amino acids into protein of muscle. 2. Accumulation and incorporation studies with the perfused rat heart. Biochem J. 1963;89: 202-9.
33. Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest. 1987;80: 1-6.
34. Fulks RM, Li JB, Goldberg AL. Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm. J Biol Chem. 1975;250: 290-8.
35. Metsios GS, Stavropoulos-Kalinoglou A, Koutedakis Y, Kitas GD. Rheumatoid cachexia: causes, significance and possible interventions. Hospital Chronicles. 2006;1: 20-6.
36. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol. 2010;6: 445-51.
37. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95: 2409-15.
38. Noguchi Y, Yoshikawa T, Marat D, Doi C, Makino T, Fukuzawa K, Tsuburaya A, Satoh S, Ito T, Mitsuse S. Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-alpha expression in skeletal muscle. Biochim Biophys Res Comm. 1998;253: 887-92.
39. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumour necrosis factor alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1998;18: 1199-202.
40. Del Aguila LF, Claffey KP, Kirwan JP. TNF-a impairs insulin signaling and insulin stimulation of glucose uptake in c2c12 muscle cells. Am J Physiol Endocrinol Metab. 1999;276: E849-55.
41. Paddon-Jones D, Sheffield-Moore M, Cree MG, Hewlings SJ, Aarsland A, Wolfe RR, Ferrando AA. Atrophy and impaired muscle protein synthesis during prolonged inactivity and stress. J Clin Endocrinol Metab. 2006;91: 4836-41.
42. Jagoe RT, Redfern CPF, Roberts RG, Gibson GJ, Goodship THJ. Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin Sci. 2002;102: 353-61.
43. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. American Society for Nutritional Sciences. J Nutr. 1999;129: 227S-37.
44. Hasselgren P-O, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg. 2001;233: 9-17.
45. Lowell BB, Ruderman NB, Goodman MN. Evidence that lysosomes are not involved in the degradation of myofibrillar proteins in rat skeletal muscle. Biochem J. 1986;234: 237-40.
46. Hasselgren P-O, James JH, Benson DW, Hall-Angerås M, Angerås U, Hiyama DT, Li S, Fischer JE. Total and myofibrillar protein breakdown in different types of rat skeletal muscle: effects of sepsis and regulation by insulin. Metabolism. 1989;38: 634-40.
47. Long CL, Birkhahn RH, Geiger JW, Betts JE, Schiller WR, Blakemore WS. Urinary excretion of 3-methylhistidine: an assessment of muscle protein catabolism in adult normal subjects and during malnutrition, sepsis, and skeletal trauma. Metabolism. 1981;30: 765-76.
48. Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, Argilès J, Lopez-Soriano LJ, Civello IM, Baccino FM, Fanelli FR, Doglietto GB. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol. 2001;280: R1518-23.
49. Williamson D, Gallagher P, Harber M, Hollon C, Trappe S. Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle. J Physiol. 2003;547: 977-87.
50. Tisdale MJ. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol. 2004;3: 209-17.
51. Lecker SH, Solomon V, Price SR, Tae KY, Mitch WE, Goldberg AL. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest. 1999;104: 1411-20.
52. Khal J, Wyke SM, Russell ST, Hine AV, Tisdale MJ. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer. 2005;93: 774-80.
53. Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, Bannon AW, Boyle WJ, Lacey DL, Han HQ. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res. 2004;64: 8193-8.
54. Li P, Lecker SH, Chen Y, Waddell ID, Goldberg AL, Reid MB. TNF-alpha increases ubiquitin-conjugation activity in skeletal muscle by up-regulating UbcH2-E220k. FASEB J. 2003;17: 1048-57.
55. Li P, Reid MB. NF-kB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol. 2000;279: R1165-70.
56. Mantovani A, Madeddu C, Maccio A. Cancer-related anorexia cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004;13: 1651-9.
57. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49: 1603-16.
58. Barreiro E, de la Puente B, Busquets S, Lopez-Soriano FJ, Gea J, Argiles JM. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett. 2005;579: 1646-52.
59. Gomes-Marcondes MCC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 2002;180: 69-74.
60. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM, López-Soriano FJ. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake: Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett. 2005;579: 717-22.
61. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO. 1996;15: 1753-65.
62. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54: 540-5.
63. Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, Herstorff RD, Chong SF, Reuter NF. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1995;13: 2856-9.
64. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84: 1463-72.
65. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KMJ, Koutedakis Y, Nevill AM, Panoulas VF, Kita M, Kitas GD. Blockade of tumour necrosis factor-α in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology. 2007;46: 1824-7.
66. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer. Br J Cancer. 1999;81: 80-6.
67. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24: 3401-7.
68. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol. 2005;23: 3830-42.
69. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R. Cancer treatment-induced alterations in muscular fitness and quality of life: the role of exercise training. Ann Oncol. 2007;18: 1957-62.
70. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98: 1154-62.
71. de Lima C, Alves LE, Iagher F, Machado AF, Bonatto SJ, Kuczera D, de Souza CF, Pequito DC, Muritiba AL, Nunes EA, Fernandes LC. Anaerobic exercise reduces tumor growth, cancer cachexia and increases macrophage and lymphocyte response in Walker 256 tumor-bearing rats. Eur J Appl Physiol. 2008;104: 957-64.
72. Lira FS, Rosa JC, Yamashita AS, Koyama CH, Batista Jr ML, Seelaender M. Endurance training induces depot-specific changes in IL-10/TNF-alpha ratio in rat adipose tissue. Cytokine. 2009;45: 80-5.
73. Keller C, Keller P, Giralt M, Hidalgo J, Pedersen BK. Exercise normalises overexpression of TNF-alpha in knockout mice. Biochem Biophys Res Commun. 2004;321: 179-82.
74. Starkie R, Ostrowski SR, Jauffred S, Febbraio MA, Klarlund B. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003;17: 884-6.
75. Pedersen BK, Hoffman-Goetz L. Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev. 2000;80: 1056-73.
76. Koch AJ. Immune response to exercise. Brazilian Journal of Boimorticity. 2010;4: 92-103.
77. Ostrowski K, Rhode T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol. 1999;51: 287-91.
78. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab. 2002;283: E1272-8.
79. Ostrowski K, Rhode T, Zacho M, Asp S, Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol. 1998;508: 949-53.
80. Leggate M, Nowell MA, Jones SA, Nimmo MA. The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress Chaperones. 2010;15: 827-33.
81. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000;529(1): 237-42.
82. Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, Neufer PD. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J. 2001;15: 2748-50.
83. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6 mechanisms for activation and possible biological roles. FASEB J. 2002;16: 1335-47.
84. Pedersen BK, Steensberg A, Schjerling P. Muscle-derived interleukin-6; possible biological effects. J Physiol. 2001;536(2): 329-37.
85. Helmark IC, Mikkelsen UR, Borglum J, Rothe A, Petersen MC, Andersen O, Langberg H, Kjaer M. Exercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial. Arthritis Res Ther. 2010;12: R126.
86. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003;285: E433-7.
87. Jonsdottir IH, Schjerling P, Ostrowski K, Asp S, Richter EA, Pedersen BK. Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles. Journal of Physiology. 2000;528: 157-63.
88. Steensberg A, Febbraio MA, Osada T, Schjerling P, van Hall G, Saltin B, Pedersen BK. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol. 2001;537(1): 633-9.
89. Keller P, Keller C, Carey AL, Jauffred S, Fischer CP, Steensberg A, Pedersen BK. Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochem Biophys Res Commun. 2003;310: 550-4.
90. Rohde T, MacLean DA, Richter EA, Kiens B, Pedersen BK. Prolonged submaximal eccentric exercise is associated with increased levels of plasma IL-6. Am J Physiol Endocrinol Metab. 1997;273: E85-91.
91. Peake J, Nosaka K, Suzuki K. Characterization of inflammatory responses to eccentric exercise in humans. Exerc Immunol Rev. 2005;11: 64-85.
92. Fischer CP, Hiscock NJ, Penkowa M, Basu S, Vessby B, Kallner A, Sjoberg LB, Pedersen BK. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol. 2004;558: 633-45.
93. Pedersen M, Steensberg A, Keller C, Osada T, Zacho M, Saltin B, Febbraio MA, Pedersen BK. Does the aging skeletal muscle maintain its endocrine function? Exerc Immunol Rev. 2004;10: 42-55.
94. Moldoveanu AI, Shephard RJ, Shek PN. Exercise elevates plasma levels but not gene expression of IL-1β, IL-6, and TNF-α in blood mononuclear cells. J Appl Physiol. 2000;89: 1499-504.
95. Ullum H, Haahr PM, Diamant M, Palmo J, Halkjaer-Kristensen J, Pedersen BK. Bicycle exercise enhances plasma IL-6 but does not change IL-1 alpha, IL-1 beta, IL-6, or TNF-alpha pre-mRNA in BMNC. J Appl Physiol. 1994;77: 93-7.
96. Nehlsen-Cannarella SL, Fagoaga OR, Nieman DC, Henson DA, Butterworth DE, Schmitt RL, Bailey EM, Warren BJ, Utter A, Davis JM. Carbohydrate and the cytokine response to 2. 5 h of running. J Appl Physiol. 1997;82: 1662-7.
97. Starkie RL, Angus DJ, Rolland J, Hargreaves M, Febbraio MA. Effect of prolonged, submaximal exercise and carbohydrate ingestion on monocyte intracellular cytokine production in humans. J Physiol. 2000;528: 647-55.
98. Starkie RL, Rolland J, Angus DJ, Anderson MJ, Febbraio MA. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-α levels after prolonged running. American Journal of Physiology - Cell Physiology. 2001;280: C769-74.
99. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and Interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75: 40-7.
100. Matthys P, Mitera T, Heremans H, van Damme J, Billiau A. Anti-gamma interferon and anti interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in d-galactosamine-sensitized and unsensitized mice. Infect Immun. 1995;63: 1158-64.
101. Mizuhara H, O'Neil E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujiwara H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med. 1994;179: 1529-37.
102. Opal SM. Anti-inflammatory cytokines. Chest. 2000;117: 1162-72.
103. Opal SM, Wherry JC, Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis. 1998;27: 1497-507.
104. Pretolani M. Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clin Exp Allergy. 1999;29: 1164-71.
105. Bogdan C, Paik J, Yoram V, Carl N. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. THEJ OURNALO F BIOLOGICACLH EMISTRY. 1992;267: 23301-8.
106. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000;343: 732-4.
107. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1)β and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine. 1993;5: 427-35.
108. van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci. 1992;89: 4845-9.
109. Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm. 2008;2008: 109502.
110. Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab. 2008;93: 543-9.
111. Kaur K, Sharma AK, Dhingra S, Singal PK. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol. 2006;41: 1023-30.
112. Leonidou L, Mouzaki A, Michalaki M, DeLastic AL, Kyriazopoulou V, Bassaris HP, Gogos CA. Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect. 2007;55: 340-6.
113. Nara M, Kanda T, Tsukui S, Inukai T, Younosuke S, Inoue S, Kobayashi I. Running exercise increases tumor necrosis factor-α secreting from mesenteric fat in insulin-resistant rats. Life Sci. 1999;65: 237-44.
114. Ji LL. Antioxidants and oxidative stress in exercise. PSEBM. 1999;222: 283-92.
115. Lawler JM, Powers SK, Visser T, van Dijk H, Kordus MJ, Ji LL. Acute exercise and skeletal muscle antioxidant and metabolic enzymes: effects of fiber type and age. Am J Physiol. 1994;265: R1344-50.
116. Powers SK, Criswell D, Lawler JM, Martin AD, Herb RA, Dudley G. Influence of exercise and fiber type on antioxidant enzyme activity in rat skeletal muscle. Am J Physiol. 1994;266: R375-80.
117. Berzosa C, Cebrian I, Fuentes-Broto L, Gomez-Trullen E, Piedrafita E, Martinez-Ballarin E, Lopez-Pingarron L, Reiter RJ, Garcia JJ. Acute exercise increases plasma total antioxidant status and antioxidant enzyme activities in untrained men. J Biomed Biotechnol. 2011;2011: 540458.
118. Lambertucci RH, Levada-Pires AC, Rossoni LV, Curi R, Pithon-Curi TC. Effects of aerobic exercise training on antioxidant enzyme activities and mRNA levels in soleus muscle from young and aged rats. Mech Ageing Dev. 2007;128: 267-75.
119. Miyazaki H, Oh-ishi S, Ookawara T, Kizaki T, Toshinai K, Ha S, Haga S, Ji LL, Ohno H. Strenuous endurance training in humans reduces oxidative stress following exhausting exercise. Eur J Appl Physiol. 2001;84: 1-6.
120. Ji LL, Stratman FW, Lardy HA. Antioxidant enzyme systems in rat liver and skeletal muscle *1: influences of selenium deficiency, chronic training, and acute exercise. Arch Biochem Biophysics. 1988;263: 150-60.
121. Duncan K., Harris S., and Ardies C. M. Running exercise may reduce risk for lung and liver cancer by inducing activity of antioxidant and phase II enzymes. Cancer Letters. 1997;116.
122. Oh-ishi S, Kizaki T, Ookawara T, Sakurai T, Izawa T, Nagata N, Ohno H. Endurance training improves the resistance of rat diaphragm to exercise-induced oxidative stress. AM J RESPIR CRIT CARE MED. 1997;156: 1579-85.
123. Vincent HK, Powers SK, Stewart DJ, Demirel HA, Shanely AR, Naito H. Short-term exercise training improves diaphragm antioxidant capacity and endurance. Eur J Appl Physiol. 2000;81: 67-74.
124. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev. 2008;88: 1243-76.
125. Leeuwenburgh C, Hollander J, Leichtweis S, Griffiths M, Gore M, Ji LL. Adaptations of glutathione antioxidant system to endurance training are tissue and muscle fiber specific. Am J Physiol Regul Integr Comp Physiol. 1997;272: R363-9.
126. Ohkuwa T, Sato Y, Naoi M. Glutathione status and reactive oxygen generation in tissues of young and old exercised rats. Acta Physiologica Scandinavica. 1997;159: 237-44.
127. Sen CK, Marin E, Kretzschmar M, Hanninen O. Skeletal muscle and liver glutathione homeostasis in response to training, exercise, and immobilization. J Appl Physiol. 1992;73: 1265-72.
128. Kretzschmar M, Müller D. Aging, training and exercise. A review of effects on plasma glutathione and lipid peroxides. Sports Medicine (Auckland, NZ). 1993;15: 196-209.
129. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19: 227-50.
130. Barañano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci. 2002;99: 16093-8.
131. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci. 1987;84: 5918-22.
132. Neuzil J, Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett. 1993;331: 281-4.
133. Khanna S, Atalay M, Lodge JK, Laaksonen DE, Roy S, Hanninen O, Packer L, Sen CK. Skeletal muscle and liver lipoyllysine content in response to exercise, training and dietary α-lipoic acid supplementation. IUBMB Life. 1998;46: 297-306.
134. Fallon KE, Sivyer G, Sivyer K, Dare A. The biochemistry of runners in a 1600 km ultramarathon. British Journal of Sports Medicine. 1999;33: 264-9.
135. Chevion S, Moran DS, Heled Y, Shani Y, Regev G, Abbou B, Berenshtein E, Stadtman ER, Epstein Y. Plasma antioxidant status and cell injury after severe physical exercise. Proc Natl Acad Sci. 2003;100: 5119-23.
136. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition. 2000;16: 1015-8.
137. Copeland GP, Leinster SJ, Daviis JC, Hipkin LJ. Insulin resistance in patients with colorectal cancer. Br J Surg. 1987;74: 1031-5.
138. Wright DW, Hansen RI, Mondon CE, Reaven GM. Sucrose-induced insulin resistance in the rat modulation by exercise and diet. Am J Clin Nutr. 1983;38: 879-83.
139. Henriksen EJ. Invited review: effects of acute exercise and exercise training on insulin resistance. J Appl Physiol. 2002;93: 788-96.
140. Segerstrom AB, Glans F, Eriksson KF, Holmback AM, Groop L, Thorsson O, Wollmer P. Impact of exercise intensity and duration on insulin sensitivity in women with T2D. Eur J Intern Med. 2010;21: 404-8.
141. Nassis GP, Papantakou K, Skenderi K, Triandafillopoulou M, Kavouras SA, Yannakoulia M, Chrousos GP, Sidossis LS. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism. 2005;54: 1472-9.
142. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab. 2000;85: 2463-8.
143. Ren J, Semenkovich CF, Gulve EA, Gao J, Holloszy JO. Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle. J Biol Chem. 1994;269: 14396-401.
144. Ivy JL. Muscle insulin resistance amended with exercise training: role of GLUT4 expression. MEDICINE & SCIENCE IN SPORTS & EXERCISE. 2004;36: 1207-11.
145. Kraniou GN, Cameron-Smith D, Hargreaves M. Acute exercise and GLUT4 expression in human skeletal muscle: influence of exercise intensity. J Appl Physiol. 2006;101: 934-7.
146. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5′AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes. 1999;48: 1-5.
147. Kennedy JW, Hirshman MF, Gervino EV, Ocel JV. R. Armour Forse, Hoenig S. J., Aronson D., Goodyear L. J., and Horton E. S. Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes. 1999;48: 1-6.
148. Throell A, Hirshman MF, Nygren J, Jorfeldt L, Wojtaszewski JFP, Dufresne SD, Horton ES, Ljungqvist O, Goodyear LJ. Exercise and insulin cause GLUT-4 translocation in human skeletal muscle. Am J Physiol Endocrinol Metab. 1999;277: E733-41.
149. Dohm GL. Invited review: r egulation of skeletal muscle GLUT-4 expression by exercise. J Appl Physiol. 2002;93: 782-7.
150. Yaspelkis 3rd BB, Castle AL, Farrar RP, Ivy JL. Contraction-induced intracellular signals and their relationship to muscle GLUT-4 concentration. Am J Physiol Endo. 1997;272: E118-W125.
151. Ren JM, Semenkovich CF, Holloszy JO. Adaptation of muscle to creatine depletion: effect on GLUT-4 glucose transporter expression. Am J Physiol Cell Physiol. 1993;264: C146-50.
152. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch possible roles in type 2 diabetes. Am J Physiol Endocrinol Metab. 1999;277: E1-10.
153. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol. 1999;87: 1990-5.
154. Ojuka EO, Nolte LA, Holloszy JO. Increased expression of GLUT-4 and hexokinase in rat epitrochlearis muscles exposed to AICAR in vitro. J Appl Physiol. 2000;88: 1072-5.
155. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol. 1998;14: 167-96.
156. Liu M, Olson AL, Edgington NP, Moye-Rowley W, Pessin JE. Myocyte enhancer factor 2 (MEF2) binding site is essential for C2C12 myotube-specific expression of the rat GLUT4 muscle-adipose facilitative glucose transporter. J Biol Chem. 1994;269: 28514-21.
157. Thai MV, Guruswamy S, Cao KT, Pessin JE, Olson AL. Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. J Biol Chem. 1998;273: 14285-92.
158. McGee SL, Hargreaves M. Exercise and myocyte enhancer factor 2 regulation in human skeletal muscle. Diabetes. 2004;53: 1208-14.
159. Wu H, Naya FJ, McKinsey TA, Mercer B, Shelton J, Chin ER, Simard AR, Michel RN, Bassel-Duby R, Olson EN, Williams RS. MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. EMBO. 2000;19: 1963-73.
160. McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA. 2000;97: 14400-5.
161. Hasten DL, Pak-Loduca J, Obert KA, Yarasheski KE. Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and 23-32 yr olds. American Journal of Physiology - Endocrinology And Metabolism. 2000;278: E620-6.
162. Balagopal P, Schimke JC, Ades P, Adey D, Nair KS. Age effect on transcript levels and synthesis rate of muscle MHC and response to resistance exercise. American Journal of Physiology - Endocrinology And Metabolism. 2001;280: E203-8.
163. Wilkinson SB, Phillips SM, Atherton PJ, Patel R, Yarasheski KE, Tarnopolsky MA, Rennie MJ. Differential effects of resistance and endurance exercise in the fed state on signalling molecule phosphorylation and protein synthesis in human muscle. J Physiol. 2008;586: 3701-17.
164. Rennie MJ, Edwards RH, Krywawych S, Davies CT, Halliday D, Waterlow JC, Millward DJ. Effect of exercise on protein turnover in man. Clin Sci. 1981;61: 627-39.
165. Rennie MJ, Edwards RH, Davies CT, Krywawych S, Halliday D, Waterlow JC, Millward DJ. Protein and amino acid turnover during and after exercise. Biochem Soc Trans. 1980;8: 499-501.
166. Miller BF, Olesen JL, Hansen M, Dossing S, Crameri RM, Welling RJ, Langberg H, Flyvbjerg A, Kjaer M, Babraj JA, Smith K, Rennie MJ. Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol. 2005;567: 1021-33.
167. Biolo G, Maggi SP, Williams BD, Tipton KD, Wolfe RR. Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. Am J Physiol. 1995;268: E514-20.
168. Kubica N, Bolster DR, Farrell PA, Kimball SR, Jefferson LS. Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2Bepsilon mRNA in a mammalian target of rapamycin-dependent manner. J Biol Chem. 2005;280: 7570-80.
169. Dreyer HC, Fujita S, Cadenas JG, Chinkes DL, Volpi E, Rasmussen BB. Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J Physiol. 2006;576: 613-24.
170. Chesley A, MacDougall JD, Tarnopolsky MA, Atkinson SA, Smith K. Changes in human muscle protein synthesis after resistance exercise. J Appl Physiol. 1991;73: 1383-8.
171. Phillips SM, Tipton KD, Asle A, Wolf SE, Wolfe RR. Mixed muscle protein synthesis and breakdown after resistance exercise in humans. Am J Physiol. 1997;273: E99-107.
172. Adams GR, Haddad F. The relationships among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. J Appl Physiol. 1996;81: 2509-16.
173. Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol. 1998;84: 1716-22.
174. Coleman ME, DeMayo F, Yin KC, Lee HM, Geskel R, Montgomeryl C, Schwartz R. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 1995;270: 12109-16.
175. Goldspink DF, Garlick PJ, McNurlan MA. Protein turnover measured in vivo and in vitro in muscles undergoing compensatory growth and subsequent denervation atrophy. Biochem J. 1983;210: 89-98.
176. Bamman MM, Shipp JR, Jiang J, Gower BA, Hunter GR, Goodman A, McLafferty CL, Urban RJ. Mechanical load increases muscle IGF-I and androgen receptor mRNA concentrations in humans. Am J Physiol Endocrinol Metab. 2001;280: E383-90.
177. Borst SE, De Hoyos DV, Garzarella L, Vincent K, Pollock BH, Lowenthal DT, Pollock ML. Effects of resistance training on insulin-like growth factor-I and IGF binding proteins. Med Sci Sports Exerc. 2000;33: 648-53.
178. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell. 2004;14: 395-403.
179. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296: 1655-7.
180. Datta SR, Brunet A, Greenberg ME. Cellular survival a play in three Akts. Genes Dev. 1999;13: 2905-27.
181. Lawlor MA, Rotwein P. Insulin-like growth factor-mediated muscle cell survival central roles for Akt and cyclin-dependent kinase inhibitor p21. Molecular and Cell Biology. 2000;20: 8983-95.
182. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2: 489-501.
183. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002;13: 2276-88.
184. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeourt A, Lawrencet JC, Glass DJ, Yancopoulos GD. Akt-mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. NATURE CELL BIOLOGY. 2001;3: 1014-9.
185. Nave BT, Ouwens MD, Withers DJ, Alessi DR, Shephard PR. Mammalian target of rapamycin is a direct target for protein kinase B identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344: 427-31.
186. Scott PH, Lawrence JC. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3 T3-L1 adipocytes. J Biol Chem. 1998;273: 34496-501.
187. Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL, Chinkes DL, Dhanani S, Volpi E, Rasmussen BB. Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocrinol Metab. 2008;294: E392-400.
188. Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, Volpi E, Rasmussen BB. Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. J Physiol. 2009;587: 1535-46.
189. Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci USA. 2002;99: 9213-8.
190. Tsakiridis T, Tsiani E, Lekas P, Bergman A, Cherepanov V, Whiteside C, Downey GP. Insulin, insulin-like growth factor-I, and platelet-derived growth factor activate extracellular signal-regulated kinase by distinct pathways in muscle cells. Biochem Biophys Res Commun. 2001;288: 205-11.
191. Wojtaszewski JFP, Lynge J, Jakobsen AB, Goodyear LJ, Richter EA. Differential regulation of MAP kinase by contraction and insulin in skeletal muscle: metabolic implications. Am J Physiol Endocrinol Metab. 1999;277: E724-32.
192. Parkington JD, LeBrasseur NK, Siebert AP, Fielding RA. Contraction-mediated mTOR, p70S6k, and ERK1/2 phosphorylation in aged skeletal muscle. J Appl Physiol. 2004;97: 243-8.
193. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121: 179-93.
194. Eliasson J, Elfegoun T, Nilsson J, Kohnke R, Ekbolm B, Blomstrand E. Maximal lengthening contractions increase p70 S6 kinase phosphorylation in human skeletal muscle in the absence of nutritional supply. Am J Physiol Endocrinol Metab. 2006;291: E1197-205.
195. Baar K, Esser K. Phosphorylation of p70S6kcorrelates with increased skeletal muscle mass following resistance exercise. Am J Physiol. 1999;276: C120-7.
196. Terzis G, Georgiadis G, Stratakos G, Vogiatzis I, Kavouras S, Manta P, Mascher H, Blomstrand E. Resistance exercise-induced increase in muscle mass correlates with p70S6 kinase phosphorylation in human subjects. Eur J Appl Physiol. 2008;102: 145-52.
197. Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE, Morrow GR. A 4-week home-based aerobic and resistance exercise program during radiation therapy a pilot randomized clinical trial. J Support Oncol. 2003;7: 158-67.
198. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, Slovinec D'Angelo ME, Wells GA. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21: 1653-9.
199. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU. Resistance training and reduction of treatment side effects in prostate cancer patients. Medicine & Science in Sports & Exercise. 2006;38: 2045-52.
200. Galvao DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, Yamaya K, McGuigan MR, Kristjanson LJ, Newton RU. Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis. 2007;11: 160-5.
201. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JKH, Lane K, Yasui Y, McKenzie DC. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25: 4396-404.
202. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiology Biomarkers & Prevention. 2005;14: 1672-80.
203. Jones LW, Eves ND, Kraus WE, Potti A, Crawford J, Blumenthal JA, Peterson BL, Douglas PS. The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer. 2010;10: 155-5.
204. Quist M, Rorth M, Zacho M, Andersen C, Moeller T, Midtgaard J, Adamsen L. High-intensity resistance and cardiovascular training improve physical capacity in cancer patients undergoing chemotherapy. Scandinavian Journal of Medicine & Science in Sports. 2006;16: 349-57.
205. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP. Prud'Homme D. G., Malone S. C., Wells G. A., Scott C. G., and Slovinec D'Angelo M. E. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27: 344-51.
206. Singh MF. DIng W., Manfredi T. J., Solares G. S., O'Neil E., Clements K. M., Ryan N. D., Kehayias J. J., Fielding R. A., and Evans W. J. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J Physiol Endocrinol Metab. 1999;277: E135-43.
207. Yarasheski KE, Pak-Loduca J, Hasten DL, Obert KA, Brown MB, Sinacore DR. Resistance exercise training increases mixed muscle protein synthesis rate in frail women and men≥ 76 yr old. Am J Physiol Endocrinol Metab. 1999;277: E118-25.
208. Rhodes EC, Martin AD, Taunton JE, Donnelly M, Warren J, Elliot J. Effects of one year of resistance training on the relation between muscular strength and bone density in elderly women. B J Sports Med. 2000;34: 18-22.
209. Hakkinen K, Kraemer WJ, Newton RU, Alen M. Changes in electromyographic activity, muscle fibre and force production characteristics during heavy resistance power strength training in middle-aged and older men and women. Acta Physiol Scand. 2001;171: 51-62.
210. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. JAMA. 1990;263: 3029-34.
211. Skelton DA, McLaughlin AW. Training functional ability in old age. Physiotherapy. 1996;82: 159-67.
212. Macaluso A, Young A, Gibb KS, Rowe DA, De Vito G. Cycling as a novel approach to resistance training increases muscle strength, power, and selected functional abilities in healthy older women. J Appl Physiol. 2003;95: 2544-53.
213. Cheema B, Abas H, Smith B, O'Sullivan A, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, Singh MF. Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol. 2007;18: 1594-601.
214. Roubenoff R, Wilson IB. Effect of resistance training on self-reported physical functioning in HIV infection. Med Sci Sports Exerc. 2001;33: 1811-7.
215. Dolan SE, Frontera W, Librizzi J, Ljungquist K, Juan S, Dorman R, Cole ME, Kanter JR, Grinspoon S. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus. Arch Intern Med. 2006;166: 1225-31.
216. Yarasheski KE, Tebas P, Stanerson B, Claxton S, Marin D, Bae K, Kennedy M, Tantisiriwat W, Powderly WG. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol. 2001;90: 133-8.